TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Prostate cancer is a leading cause of cancer death in men, with limited effective treatments for advanced stages.
• Toll-like receptors (TLRs) play a complex role in prostate cancer, with TLR9 implicated in both tumor progression and inhibition.
• Understanding TLR9's precise role is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the effect of TLR9 stimulation on prostate cancer progression.
• To evaluate the potential of TLR9 agonists as a therapeutic agent for prostate cancer.

Main Methods:

• Utilized an immune-competent, syngeneic orthotopic mouse model of prostate cancer.
• Administered the synthetic TLR9 agonist CPG-1668 to stimulate a systemic immune response.
• Analyzed tumor size, immune cell infiltration (M1 macrophages, T cells), and tumor cell viability in vitro.

Main Results:

• Systemic TLR9 stimulation with CPG-1668 significantly impaired prostate tumorigenesis, leading to smaller tumors.
• TLR9 activation reduced the abundance of M1 macrophages and T cells within tumors.
• In vitro, TLR9 stimulation did not affect tumor cell viability but suppressed cancer cell growth when applied to macrophages via type I IFN.

Conclusions:

• Systemic TLR9 stimulation exerts an antitumorigenic effect on prostate cancer.
• The therapeutic benefits of CPG-1668 are primarily mediated by an enhanced antitumor immune response.
• TLR9 agonists represent a promising therapeutic avenue for treating prostate cancer.